CA2942954A1 - Methods for increasing red blood cell levels and treating ineffective erythropoiesis - Google Patents

Methods for increasing red blood cell levels and treating ineffective erythropoiesis Download PDF

Info

Publication number
CA2942954A1
CA2942954A1 CA2942954A CA2942954A CA2942954A1 CA 2942954 A1 CA2942954 A1 CA 2942954A1 CA 2942954 A CA2942954 A CA 2942954A CA 2942954 A CA2942954 A CA 2942954A CA 2942954 A1 CA2942954 A1 CA 2942954A1
Authority
CA
Canada
Prior art keywords
activin
gdf11
antibody
trap
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2942954A
Other languages
English (en)
French (fr)
Inventor
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
John Knopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA2942954A1 publication Critical patent/CA2942954A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2942954A 2014-03-21 2015-03-20 Methods for increasing red blood cell levels and treating ineffective erythropoiesis Pending CA2942954A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461969073P 2014-03-21 2014-03-21
US61/969,073 2014-03-21
US201462021923P 2014-07-08 2014-07-08
US62/021,923 2014-07-08
PCT/US2015/021880 WO2015143403A1 (en) 2014-03-21 2015-03-20 Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11

Publications (1)

Publication Number Publication Date
CA2942954A1 true CA2942954A1 (en) 2015-09-24

Family

ID=54145413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942954A Pending CA2942954A1 (en) 2014-03-21 2015-03-20 Methods for increasing red blood cell levels and treating ineffective erythropoiesis

Country Status (9)

Country Link
US (2) US20160046690A1 (enExample)
EP (1) EP3119418B1 (enExample)
JP (2) JP2017509647A (enExample)
KR (2) KR102520970B1 (enExample)
CN (1) CN106659769A (enExample)
AU (3) AU2015231022B2 (enExample)
CA (1) CA2942954A1 (enExample)
MA (1) MA39722A (enExample)
WO (1) WO2015143403A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053234A1 (en) * 2016-09-15 2018-03-22 Acceleron Pharma, Inc. Twisted gastrulation polypeptides and uses thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CA2964808C (en) 2014-10-30 2023-06-27 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
SI3286206T1 (sl) 2015-04-22 2021-07-30 Biogen Ma Inc. Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
HUE067225T2 (hu) * 2016-07-27 2024-10-28 Acceleron Pharma Inc Mielofibrózis kezelésére szolgáló készítmények
KR102761094B1 (ko) 2016-10-05 2025-02-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN119241685A (zh) 2016-11-10 2025-01-03 科乐斯疗法公司 激活素受体iia型变体及其使用方法
HUE068733T2 (hu) 2017-06-14 2025-01-28 Celgene Corp Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére
CN107828719B (zh) * 2017-09-14 2020-05-19 暨南大学 Gdf11在脂肪间充质干细胞成骨分化中的应用
CN111801112A (zh) 2017-11-09 2020-10-20 科乐斯疗法公司 激活素受体iia型变体及其使用方法
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
US12263205B2 (en) 2018-04-30 2025-04-01 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
WO2019217715A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP7663882B6 (ja) * 2020-01-20 2025-06-10 ルダキュア コーポレーション Ｔｒｐｖ１活性媒介疾患治療用の薬学的組成物
CA3176735A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4514971A1 (en) * 2022-04-29 2025-03-05 University Of Massachusetts Selective rna-modulating agents
WO2025040002A1 (zh) * 2023-08-21 2025-02-27 苏州炫景生物科技有限公司 靶向inhbe基因的双链寡核苷酸、缀合物、组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877075A4 (en) * 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
US8128933B2 (en) * 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
WO2008076437A2 (en) * 2006-12-18 2008-06-26 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
TWI626945B (zh) * 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5912078B2 (ja) * 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
CN102655872B (zh) * 2009-08-13 2016-01-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
KR20140084211A (ko) * 2011-10-17 2014-07-04 악셀레론 파마 인코포레이티드 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
EP2844668A1 (en) * 2012-05-03 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
CA2889286A1 (en) * 2012-10-24 2014-05-01 Celgene Corporation Methods for treating anemia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053234A1 (en) * 2016-09-15 2018-03-22 Acceleron Pharma, Inc. Twisted gastrulation polypeptides and uses thereof
US12145970B2 (en) 2016-09-15 2024-11-19 Acceleron Pharma Inc. Twisted gastrulation polypeptides and uses thereof

Also Published As

Publication number Publication date
KR102520970B1 (ko) 2023-04-12
WO2015143403A1 (en) 2015-09-24
CN106659769A (zh) 2017-05-10
AU2015231022A1 (en) 2016-09-29
JP7154250B2 (ja) 2022-10-17
AU2015231022B2 (en) 2021-02-04
AU2023219885A1 (en) 2023-09-14
KR20230004942A (ko) 2023-01-06
KR20160127148A (ko) 2016-11-02
EP3119418B1 (en) 2022-02-23
US20210155672A1 (en) 2021-05-27
EP3119418A1 (en) 2017-01-25
EP3119418A4 (en) 2018-01-03
MA39722A (fr) 2021-06-02
US20160046690A1 (en) 2016-02-18
JP2017509647A (ja) 2017-04-06
JP2020111621A (ja) 2020-07-27
AU2021200301A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
AU2021202382B2 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
US20210155672A1 (en) Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US11260107B2 (en) Methods and compositions for treating ulcers
US10829531B2 (en) Methods for treating myelodysplastic syndromes and sideroblastic anemias
US20220233697A1 (en) Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2017302282A1 (en) Methods and compositions for treating myelofibrosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200316

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20240920

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260221